As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area. “We ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results